Mast cells are tissue-resident immune cells best known for driving allergic reactions while also contributing to host defense and tissue repair. They were first described by Paul Ehrlich in 1878, named for their granule-rich appearance (“mast” meaning “fattened”). Unlike many circulating leukocytes, mast cells typically mature in peripheral tissues after leaving the bone marrow as immature progenitors.
Mast cells act as rapid “sentinel” cells positioned at body surfaces that meet the environment. They integrate signals from antibodies, complement, cytokines, and microbes to trigger inflammation or modulation of immune responses. In addition to allergy, they influence wound healing, angiogenesis, and aspects of chronic inflammatory disease. For broader context, see Immune System Overview and Innate Immunity.
Mast cells arise from hematopoietic stem cells and travel through blood as committed progenitors, then complete maturation within tissues under local cues. A key growth factor is stem cell factor (SCF), acting through the receptor KIT (CD117), which is essential for mast cell survival and expansion. Interleukins such as IL‑3 (in mice) and IL‑4/IL‑9/IL‑33 (context dependent) can further shape mast cell numbers and phenotype.
They are abundant in skin, airways, and the gastrointestinal tract, and they cluster near blood vessels, lymphatics, nerves, and epithelial barriers. Quantitatively, densities vary widely by tissue and disease state; in human skin, mast cell counts are commonly reported on the order of tens to a few hundred cells per mm2 in histologic sections, with higher values in inflamed lesions. Even in healthy tissue, their strategic placement lets a relatively small population exert outsized effects through potent mediators released within seconds to minutes.
The classic activation route is IgE-dependent signaling through the high-affinity IgE receptor FcεRI. When allergen cross-links IgE bound to FcεRI, mast cells rapidly degranulate and then produce new lipid mediators and cytokines. This mechanism underlies immediate hypersensitivity reactions and is central to Allergic Disease.
Mast cells also respond through many non-IgE pathways, including complement receptors (e.g., C3aR and C5aR), pattern-recognition receptors, cytokine receptors, and “alarmins” released by stressed epithelium such as IL‑33. Drugs, temperature changes, mechanical stimulation, and venoms can activate mast cells in susceptible individuals. A clinically important non-IgE pathway involves the G protein–coupled receptor MRGPRX2, implicated in some pseudoallergic drug reactions and chronic urticaria phenotypes.
Upon activation, mast cells can release preformed granule mediators within seconds to minutes, including histamine, heparin, and proteases such as tryptase and chymase. They also synthesize lipid mediators (e.g., prostaglandin D2 and leukotriene C4) within minutes and produce cytokines/chemokines (e.g., TNF, IL‑4, IL‑5, IL‑13) over hours. This layered timing helps explain why symptoms can progress from immediate itching and flushing to more sustained bronchoconstriction or tissue inflammation.
Histamine increases vascular permeability and stimulates sensory nerves, contributing to hives and pruritus, while leukotrienes can strongly constrict airways. Tryptase is a widely used biomarker: in suspected anaphylaxis, a commonly applied interpretive rule is that an acute tryptase rise of at least “(1.2 × baseline) + 2 ng/mL” supports systemic mast cell activation. Clinically, anaphylaxis is not rare; population-based estimates in multiple countries suggest an annual incidence on the order of ~50–100 episodes per 100,000 person-years, though rates vary by region and methodology. For symptom patterns and emergency relevance, see Anaphylaxis.
In health, mast cells contribute to barrier defense by sensing pathogens and coordinating local vascular changes that recruit other immune cells. They also interact with nerves and blood vessels, influencing pain, itch, and microcirculation, and they can participate in tissue remodeling and fibrosis depending on context. These functions make them important not only in acute reactions but also in chronic inflammatory states.
In disease, mast cells are central in allergic rhinitis, asthma, atopic dermatitis, food allergy, and urticaria, where they amplify type 2 inflammation and immediate hypersensitivity. They are also implicated in certain gastrointestinal disorders, some forms of chronic pruritus, and interstitial cystitis/bladder pain syndrome, although causality and subtypes remain under active investigation. A distinct category is clonal mast cell disease: systemic mastocytosis is a myeloid neoplasm characterized by abnormal mast cell accumulation, most commonly associated with the KIT D816V mutation (reported in the great majority of adult systemic mastocytosis cases in modern series, often >80%). For related entities, see Mastocytosis and Type 2 Inflammation.
Myth: Mast cells are only “allergy cells.” Evidence shows mast cells participate in antimicrobial defense, wound healing, vascular regulation, and neuro-immune signaling; allergy is a prominent but not exclusive function. Their mediator repertoire and tissue localization allow roles that extend beyond IgE-mediated reactions.
Myth: High tryptase always means anaphylaxis. Baseline tryptase can be chronically elevated in systemic mastocytosis and in hereditary alpha-tryptasemia, and acute rises may be modest or absent in some anaphylaxis cases depending on timing and phenotype. This is why clinicians compare acute to baseline levels and interpret tryptase alongside clinical criteria. For biomarker context, see Tryptase Testing.
Myth: “Mast cell activation” explains any unexplained symptom cluster. Mast cell activation syndrome (MCAS) has proposed diagnostic criteria requiring recurrent systemic symptoms consistent with mediator release, objective evidence of mediator elevation, and response to mediator-targeting therapy. Over-broad use of the label without objective mediator data can delay correct diagnosis of endocrine, cardiovascular, neurologic, or psychiatric conditions. When MCAS is considered, differential diagnosis and careful measurement timing are essential; see Mast Cell Activation Syndrome.
Myth: Avoiding all histamine-containing foods is a universal solution. “Histamine intolerance” remains heterogeneous, and symptom triggers vary widely between individuals and conditions; some benefit from targeted dietary modification, while others do not. Evidence-based management typically prioritizes identifying true allergies, ruling out clonal mast cell disease when indicated, and using proven therapies such as H1/H2 antihistamines, leukotriene modifiers, and—in selected allergic disease—anti-IgE or other biologics. For management frameworks, see Antihistamines.